BioMS Trial of MBP8298 for SPMS
Submitted by art on Tue, 2007-06-26 06:48.
BioMS Medical Corp announced that the first subjects have been enrolled in MAESTRO-03, its U.S. pivotal phase III clinical trial of MBP8298, a proprietary synthetic peptide for the treatment of NS. The randomized, double-blind study is enrolling approximately 510 secondary progressive MS patients at approximately 60 sites across the U.S. who will be administered either MBP8298 or placebo intravenously every six months for a period of two years.
Interested in enrolling? Go here.